The aim of this study was to show whether immunotherapy should be administered in patients with renal cell carcinoma after radical nephrectomy in N0 and N1 stage of disease. The research was conducted in 60 patients with renal adenocarcinoma after radical nephrectomy. The study group included two subgroups of patients: the treatment group consisted of 30 patients receiving immunotherapy, of whom 15 had N1 disease stage and 15 had N0 disease stage; and the observation group consisted of 30 patients who did not receive immunotherapy, of whom 15 had N1 disease stage and 15 had N0 disease stage. It was shown that the administration of immunotherapy in N0 stage neither improved the overall survival nor postponed the appearance of metastases and that immunotherapy in N1 stage even worsened the prognosis in overall survival as compared with the observation group. There is no benefit of administering immunotherapy in patients with N0 and N1 stage of disease after radical nephrectomy.